Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Maze Therapeutics (MAZE) Revenue (2024 - 2026)

Maze Therapeutics' Revenue history spans 2 years, with the latest figure at $20.0 million for Q1 2026.

  • On a quarterly basis, Revenue changed N/A to $20.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $20.0 million, a N/A change, with the full-year FY2024 number at $15.0 million, changed N/A from a year prior.
  • Revenue hit $20.0 million in Q1 2026 for Maze Therapeutics, up from -$152.5 million in the prior quarter.
  • Over the last five years, Revenue for MAZE hit a ceiling of $150.0 million in Q2 2024 and a floor of -$152.5 million in Q4 2024.